HealthLGBTQ
HealthHCV
HealthCBA
HealthHIV
Facebook Twitter Linkedin Youtube
Table of Contents

A Multi-Module Program for Advanced HIV Care and Treatment Providers: From Managing Comorbidities to Implementing Long-Acting Injectables

 

As there are rapid advancements in innovative HIV treatment, provider education must be timely and relevant to support providers to manage the complexity of patient care — from long-acting agents and injectables to new strategies for managing comorbidities and treatment resistance. Start your HIV innovation journey by enrolling in the free HealthHIV HIV Treatment Innovation™ Certificate Program that features leading experts in the field discussing the latest strategies in HIV treatment and management.

By participating in this free, one-of-a-kind program, experienced providers will:

  • Develop skills to optimize HIV care
  • Receive a certificate in HIV treatment innovation
  • Earn up to 5.5 credit hours (CME, MOC, AAPA, NCPD, CPE )
  • Stay connected to the dynamic HIV treatment landscape so that your patients can benefit from new innovations!

Providers will receive the latest updates in HIV treatment innovations while establishing a solid foundational understanding of key areas such as comorbidities and the unique needs of older adults, all reinforced through guided patient-case scenarios which feature treatment individualization strategies for enhanced clinical applicability.

Program Enrollment

If you previously enrolled in a training on eHealthHIV.org, you only need to check your information and update if necessary.

Enroll Now

What’s New in 2024?

The update and recertification of the HealthHIV HIV Treatment Innovation Certificate Program was released on November 4, 2024. There are a few key updates to be aware of:

  • All modules are updated with state-of-the-science clinical data and information.
  • A complex case study module has been added to allow learners to apply their knowledge and skills in HIV treatment individualization to patient case scenarios.
  • Additional credits/contact hours have been added (CME, MOC, AAPA, NCPD, CPE) for a total of up to 5.50 for completion of the certificate program.

Target Audience

This activity is intended for experienced HIV care providers (HIV and ID specialists), as well as primary care providers and general practitioners (includes MD/DO, NP, PA), nurses, pharmacists, and other professionals involved in the care of PWH.

  • Media: Enduring Material
  • Release date for Modules 1-6: November 4, 2024
  • Expiration date for Modules 1-6: November 3, 2025
  • Time to Complete Modules 1-5: 60 minutes
  • Time to Complete Module 6: 30 minutes

Educational Objectives

After completing this activity, the participant should be better able to:

  • Deliver comprehensive and individualized HIV care, including ART treatment and management of antiviral resistance and common coinfections and comorbidities.
  • Recognize the benefits and flexibility of available regimens for vulnerable patients with HIV, including older adults and treatment-experienced patients.
  • Apply individualized therapy for patients with HIV that is based on new and emerging strategies and addresses the diverse needs and preferences of individual patients (e.g., adolescents, pregnant persons, unstably housed individuals, and those with substance use disorders) to promote health equity.
  • Describe new and investigational ART regimens and how they can be utilized to optimize HIV treatment.

Course Overview

Module 1

Innovations in Antiretroviral Therapies to Optimize HIV Treatment

Access Module 1
Faculty

Melissa E. Badowski, PharmD, MPH, FIDSA, FCCP, BCIDP, BCPS, AAHIVP
Clinical Professor, Infectious Diseases Pharmacotherapy, University of Illinois at Chicago, College of Pharmacy
HIV Telemedicine Clinical Specialist, Illinois Department of Corrections, Chicago, IL

Module Description

This module provides an update on recommended and investigational ARV therapies for optimal HIV care and treatment in HIV care, primary care, and general medicine.

Educational Objectives

Upon completion of this activity, participants should be able to:

  • Describe recent updates to HIV treatment guidelines, including guidance for optimal HIV treatment in HIV care and primary care settings
  • Explain innovations in antiretroviral therapy (ART), such as long-acting injectable ART (LA ART)
  • Identify strategies to monitor patient response to therapy and HIV treatment adherence
  • Discuss switching patients to more simplified HIV treatment regimens

Management of Common Comorbidities for People Living with HIV

Access Module 2
Faculty

David Alain Wohl, MD
Professor of Medicine in the Division of Infectious Diseases, University of North Carolina School of Medicine
Co-Principal Investigator, Global UNC Infectious Diseases Clinical Trial Unit
Site Leader, HIV Prevention and Treatment Clinical Trials Unit, Chapel Hill, NC

Module Description

This module provides considerations for managing and preventing common comorbidities, co-infections and opportunistic infections among PWH.

Educational Objectives

Upon completion of this activity, participants should be able to:

  • Identify common comorbidities and co-infections (CIs) among people with HIV and their impact on treatment decisions
  • Summarize recent updates to HIV treatment guidelines related to co-infections and opportunistic infections (OIs)
  • Identify strategies to manage common comorbidities and co-infections, including notable medication contraindications
  • Explain the importance of prevention and wellness discussions with PWH, that includes vaccinations, to reduce impact of CIs and OIs
Module 3

Considerations in the Management of HIV in Older Adults

Access Module 3
Faculty

Jonathan S. Appelbaum, MD, FACP, AAHIVS
Professor Emeritus, Florida State University College of Medicine
Medical Director, Care Point Health and Wellness, Tallahassee, FL

Module Description

This module provides considerations for managing HIV care among older adults and long-term HIV survivors.

Educational Objectives

Upon completion of this activity, participants should be able to:

  • Identify common comorbidities most prevalent in older adults with HIV, based on findings from the REPRIEVE study
  • Discuss strategies and special considerations for managing HIV care in older adults who did not initiate early start on treatment
  • Evaluate the potential impact of long-term antiretroviral therapy on cardiometabolic risk and other comorbidities in older adults and long-term HIV survivors
  • Develop strategies for managing both antiretroviral therapy and cardiometabolic risk factors in patients with HIV

Improving Health Equity in HIV Management

Access Module 4
Faculty

Kathleen A. McManus, MD, MSc, FIDSA
Associate Professor of Medicine, Division of Infectious Diseases and International Health, University of Virginia School of Medicine
Medical Director, UVA Ryan White HIV Clinic, Charlottesville, VA

Module Description

This module provides evidence-based HIV treatment optimization strategies for delivering quality HIV care among key populations.

Educational Objectives

​​Upon completion of this activity, participants should be able to:

  • Explain inequities in HIV and social determinants of health impacting people with HIV (PWH)
  • Describe intersectionality of social determinants of health that impact HIV treatment among key populations
  • Identify model practices for optimizing HIV management/treatment among patients with competing priorities (e.g. persons experiencing homelessness, substance use disorders, transgender persons, young adults)

Management of Treatment-Experienced Patients with HIV Drug Resistance

Access Module 5
Faculty

Monica Gandhi, MD, MPH
Professor of Medicine, Associate Chief in the Division of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco
Medical Director, Ward 86 HIV Clinic at San Francisco General Hospital, San Francisco, CA

Module Description

This module provides information on the latest strategies for managing treatment of patients with HIV drug resistance.

Educational Objectives

​​Upon completion of this activity, participants should be able to:

  • Identify impacts of HIV drug resistance on patients and communities
  • Identify the causes of virologic failure and methods to assess virologic failure and HIV drug resistance
  • Identify steps for constructing new treatment regimens for patients with HIV drug resistance
  • Identify considerations for special populations with HIV drug resistance

Applying HIV Treatment Individualization in Patient Case Scenarios

Access Module 6
Faculty

Asa E. Radix, MD, PhD, MPH, FIDSA
Associate Professor of Clinical Epidemiology, Columbia University, Mailman School of Public Health
Infectious Disease/HIV Specialist, Callen-Lorde Community Health Center, New York, NY

Module Description

This module offers comprehensive patient cases that require learners to apply knowledge from Modules 1-5 in case-based scenarios.

Educational Objectives

​​Upon completion of this activity, participants should be able to:

  • Evaluate HIV management needs of older adults with HIV
  • Identify unique considerations of HIV management for transgender women
  • Apply HIV treatment knowledge to determine optimal ART regimens for patients

Accreditation, Credit, and Support

All modules are certified and participants can earn up to 5.5 Credits/Contact Hours (CME, MOC, NCPD, AAPA, CPE) for completion of the certificate.

HealthHIV
Medical Learning Institute Inc.
Jointly Accredited Provider with Commendation — Interprofessional Continuing Education

In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and HealthHIV. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medical Learning Institute, Inc. (MLI) designates the modules within this enduring material for the following AMA PRA Category 1 Credits™ :

  • Module 1: up to 1.0
  • Module 2: up to 1.0
  • Module 3: up to 1.0
  • Module 4: up to 1.0
  • Module 5: up to 1.0
  • Module 6: up to 0.5

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM CME MOC AccreditedSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn the following MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • Module 1: up to 1.0
  • Module 2: up to 1.0
  • Module 3: up to 1.0
  • Module 4: up to 1.0
  • Module 5: up to 1.0
  • Module 6: up to 0.5

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

UEMSThe European Union of Medical Specialists-European Accreditation Council for Continuing Medical Education (UEMS-EACCME®) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit(s)™ into European CME credit (ECMEC®) should contact the UEMS (www.uems.eu).
AAPA Category 1 CMEMedical Learning Institute, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for the following AAPA Category 1 CME credit. Approval is valid until November 3, 2025. PAs should only claim credit commensurate with the extent of their participation.
  • Module 1: up to 1.0
  • Module 2: up to 1.0
  • Module 3: up to 1.0
  • Module 4: up to 1.0
  • Module 5: up to 1.0
  • Module 6: up to 0.5

Successful completion of this nursing continuing professional development activity will be awarded the following contact hour and contact hour in the area of pharmacology.

Module NCPD Contact Hour Pharmacology Contact Hour
Module 1: Innovations in Antiretroviral Therapies to Optimize HIV Treatment up to 1.0 0.5
Module 2: Management of Common Comorbidities for People Living with HIV up to 1.0 1.0
Module 3: Considerations in the Management of HIV in Older Adults up to 1.0 0.75
Module 4: Improving Health Equity in HIV Management up to 1.0 None
Module 5: Management of Treatment-Experienced Patients with HIV Drug Resistance up to 1.0 1.0
Module 6: Applying HIV Treatment Individualization in Patient Case Scenarios up to 0.5 0.5

Medical Learning Institute, Inc. designates this knowledge-based continuing education activity for the following contact hour and CEU of the Accreditation Council for Pharmacy Education.

Module CPE Contact Hour UAN Number
Module 1: Innovations in Antiretroviral Therapies to Optimize HIV Treatment up to 1.0 (0.1 CEU) JA0007322-9999-24-085-H01-P
Module 2: Management of Common Comorbidities for People Living with HIV up to 1.0 (0.1 CEU) JA0007322-9999-24-086-H01-P
Module 3: Considerations in the Management of HIV in Older Adults up to 1.0 (0.1 CEU) JA0007322-9999-24-087-H01-P
Module 4: Improving Health Equity in HIV Management up to 1.0 (0.1 CEU) JA0007322-9999-24-088-H01-P
Module 5: Management of Treatment-Experienced Patients with HIV Drug Resistance up to 1.0 (0.1 CEU) JA0007322-9999-24-089-H01-P
Module 6: Applying HIV Treatment Individualization in Patient Case Scenarios up to 0.5 (0.05 CEU) JA0007322-9999-24-090-H01-P
IPCE CreditThis activity was planned by and for the healthcare team, and learners will receive the following Interprofessional Continuing Education (IPCE) credit for learning and change.
  • Module 1: up to 1.0
  • Module 2: up to 1.0
  • Module 3: up to 1.0
  • Module 4: up to 1.0
  • Module 5: up to 1.0
  • Module 6: up to 0.5

Support Statement

This program has been supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure and Conflict of Interest Policy

Medical Learning Institute, Inc. and HealthHIV are committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.

Faculty Disclosures

Melissa E. Badowski, PharmD, MPH, FCCP, FIDSA, BCIDP, BCPS, AAHIVP
University of Illinois Chicago
Chicago, IL
Melissa E. Badowski, PharmD, MPH, FCCP, FIDSA, BCIDP, BCPS, AAHIVP, has no relevant financial relationships with ineligible companies to disclose for this educational activity.

David A. Wohl, MD
UNC School of Medicine – Institute for Global Health and Infectious Diseases
Chapel Hill, NC
David A. Wohl, MD, has a financial interest/relationship or affiliation in the form of:

  • Consultant/Advisor: EMD Serono, Gilead Sciences, Janssen, Merck, Regeneron, Theratechnologies, ViiV
  • Research funding: Gilead Sciences, Merck, ViiV
  • Contracted researcher: Gilead Sciences, Merck, ViiV

Jonathan S. Appelbaum, MD, FACP, AAHIVS
Florida State University College of Medicine
Care Point Health and Wellness
Tallahassee, FL
Jonathan S. Appelbaum, MD, FACP, AAHIVS, has a financial interest/relationship or affiliation in the form of:

  • Consultant/Advisor: EMD Serono (ended 5/2024)

Kathleen A. McManus, MD, MSc, FIDSA
University of Virginia, School of Medicine
Charlottesville, VA
Kathleen A. McManus, MD, MSc, has a financial interest/relationship or affiliation in the form of:

  • Stocks: Gilead Sciences (ended 11/2022)

Monica Gandhi, MD, MPH
University of San Francisco – School of Medicine
San Francisco, CA
Monica Gandhi, MD, MPH, has no relevant financial relationships with ineligible companies to disclose for this educational activity.

Asa E. Radix, MD, PhD, MPH, FIDSA
Columbia University Mailman – School of Public Health
New York, NY
Asa E. Radix, MD, PhD, MPH, FACP, has no relevant financial relationships with ineligible
companies to disclose for this educational activity.

All of the relevant financial relationships of individuals for this activity have been mitigated.

Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and HealthHIV, the joint provider, do not have any relevant financial relationships to disclose with ineligible companies.

Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. Your certificate will be available on eHealthHIV.org. If you have questions regarding your certificate, please contact Beth Brooks via email at [email protected].

For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.

For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit.

For Pharmacists, MLI will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.

About This Activity
Medical Learning Institute, Inc. and HealthHIV are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc. and HealthHIV.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.

Questions and Answers

What if I have trouble logging in/ accessing a course on eHealthHIV.org?

If you are a US-based provider, you may be asked to create and/or update your profile before enrolling. Please be sure all required fields are completed in the profile form before selecting submit. If you are a non-US provider, and are having trouble accessing a course, please know that our learning management system will soon be configured to accommodate learners from other countries outside the US.

What if I am a non-US provider?

We are working to ensure support for international learners, and will provide more information about accessing our courses soon. In the meantime, if you’d like to access courses or have questions about access, please email [email protected] or [email protected].

How do I find my certificate?

Please ensure you have completed a course’s post-test (if applicable) and evaluation survey before choosing the activity to obtain your certificate of completion. Your certificate of completion may take a few days to arrive by email, and it may be directed to a junk or spam folder.

Is the program free?

You may access this program, and all of HealthHIV’s certification programs, at no cost.

© Copyright 2024 HealthHIV. All rights reserved.

Privacy Policy | Fediverse/Mastodon